Catheter Precision Expands Clinical Data for VIVO System

Catheter Precision, Inc. (NYSE/American: VTAK), a company focused on advanced cardiac electrophysiology products, announced updates regarding their VIVO non-invasive mapping system. Over the past 60 days, the company has highlighted VIVO at industry meetings, including the European Society of Cardiology (ESC) congress.

During the ESC meeting, Professor Tarv Dhanjal presented data from a study involving 20 patients. The study shows a 90% procedural success rate in patients with scar-related VT. The study aims to enroll 50 patients, with final data anticipated by 2025.

In October, Catheter Precision will present at the International VT Symposium, ISCAT, and SCRN conferences. The company also reported successful VIVO system installations and initial procedures in Doha, Qatar.

Marie-Claude Jacques, Chief Commercial Officer, announced ongoing evaluations at over 25 centers in the US, with eight new sites to begin evaluations soon.